[go: up one dir, main page]

WO2007045247A3 - Fibroblast growth factor receptor-derived peptides - Google Patents

Fibroblast growth factor receptor-derived peptides Download PDF

Info

Publication number
WO2007045247A3
WO2007045247A3 PCT/DK2006/000585 DK2006000585W WO2007045247A3 WO 2007045247 A3 WO2007045247 A3 WO 2007045247A3 DK 2006000585 W DK2006000585 W DK 2006000585W WO 2007045247 A3 WO2007045247 A3 WO 2007045247A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
amino acid
fgfrs
fibroblast growth
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/000585
Other languages
French (fr)
Other versions
WO2007045247A2 (en
Inventor
Vladimir Berezin
Vladislav V Kiselyov
Elisabeth Bock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enkam Pharmaceuticals AS
Original Assignee
Enkam Pharmaceuticals AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals AS filed Critical Enkam Pharmaceuticals AS
Priority to JP2008535889A priority Critical patent/JP2009511614A/en
Priority to EP06791473A priority patent/EP1940875A2/en
Publication of WO2007045247A2 publication Critical patent/WO2007045247A2/en
Publication of WO2007045247A3 publication Critical patent/WO2007045247A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention relates to novel peptides capable of binding to a receptor of the fibroblast growth factor receptor family (FGFRs) and modulating activity of said receptor. The peptides of the invention are fragments of FGFRs, wherein said fragments comprise amino acid residues involved in the reciprocal interaction of the Immunoglobulin-like modules 2 (Ig2) and Immunoglobulin-like module 1 (Ig1) of FGFR. The invention discloses amino acid sequences derived from the reciprocal Ig 1 -to-lg2 binding site of FGFR and relates to use of the peptides comprising said amino acid sequences for the treatment of different pathological conditions, wherein FGFRs play a prominent role. Accordingly, pharmaceutical compositions comprising the compounds of the invention are also concerned.
PCT/DK2006/000585 2005-10-19 2006-10-17 Fibroblast growth factor receptor-derived peptides Ceased WO2007045247A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008535889A JP2009511614A (en) 2005-10-19 2006-10-17 Fibroblast growth factor receptor-derived peptide
EP06791473A EP1940875A2 (en) 2005-10-19 2006-10-17 Fibroblast growth factor receptor-derived peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501466 2005-10-19
DKPA200501466 2005-10-19

Publications (2)

Publication Number Publication Date
WO2007045247A2 WO2007045247A2 (en) 2007-04-26
WO2007045247A3 true WO2007045247A3 (en) 2007-06-14

Family

ID=37808015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000585 Ceased WO2007045247A2 (en) 2005-10-19 2006-10-17 Fibroblast growth factor receptor-derived peptides

Country Status (3)

Country Link
EP (1) EP1940875A2 (en)
JP (1) JP2009511614A (en)
WO (1) WO2007045247A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435472A1 (en) * 2009-05-27 2012-04-04 Københavns Universitet Fibroblast growth factor receptor-derived peptides binding to ncam
US8999937B2 (en) * 2011-02-28 2015-04-07 Indiana University Research And Technology Corporation Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis
JPWO2024195709A1 (en) * 2023-03-17 2024-09-26

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010767A2 (en) * 2000-07-28 2002-02-07 The Administrators Of The Tulane Educational Fund Assay methods for identifying compounds which may protect stratified squamous epithelium against damage by noxious substances
WO2004056865A2 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010767A2 (en) * 2000-07-28 2002-02-07 The Administrators Of The Tulane Educational Fund Assay methods for identifying compounds which may protect stratified squamous epithelium against damage by noxious substances
WO2004056865A2 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BYERS S ET AL: "FIBROBLAST GROWTH FACTOR RECEPTORS CONTAIN A CONSERVED HAV REGION COMMON TO CADHERINS AND INFLUENZA STRAIN A HEMAGGLUTININS A ROLE IN PROTEIN-PROTEIN INTERACTIONS?", DEVELOPMENTAL BIOLOGY, vol. 152, no. 2, 1992, pages 411 - 414, XP009080414, ISSN: 0012-1606 *
EREZ NOAM ET AL: "Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement of fibroblast growth factor receptor-mediated signalling.", EXPERIMENTAL CELL RESEARCH 1 APR 2004, vol. 294, no. 2, 1 April 2004 (2004-04-01), pages 366 - 378, XP002424156, ISSN: 0014-4827 *
KISELYOV VLADISLAV V ET AL: "Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1", PROTEIN SCIENCE, vol. 15, no. 10, October 2006 (2006-10-01), pages 2318 - 2322, XP009080395, ISSN: 0961-8368 *
LAROCCA D ET AL: "Establishment of epitope-defined monoclonal antibodies with specificity for fibroblast growth factor receptor types 1 and 2.", HYBRIDOMA FEB 1998, vol. 17, no. 1, February 1998 (1998-02-01), pages 21 - 31, XP009080483, ISSN: 0272-457X *
MOHAMMADI M ET AL: "Structural basis for fibroblast growth factor receptor activation", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 16, no. 2, April 2005 (2005-04-01), pages 107 - 137, XP004874948, ISSN: 1359-6101 *
OLSEN SHAUN K ET AL: "Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 27 JAN 2004, vol. 101, no. 4, 27 January 2004 (2004-01-27), pages 935 - 940, XP002424153, ISSN: 0027-8424 *
WILLEMS JEAN ET AL: "Reduction of extracellular superoxide dismutase activity by decapeptide derived from FGF-receptor", CELL BIOLOGY INTERNATIONAL, vol. 19, no. 11, 1995, pages 935 - 937, XP002424157, ISSN: 1065-6995 *

Also Published As

Publication number Publication date
EP1940875A2 (en) 2008-07-09
WO2007045247A2 (en) 2007-04-26
JP2009511614A (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2007070659A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007079130A3 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
NO20082716L (en) Compositions and Methods for Preparing a Composition
WO2007115571A3 (en) Erbb receptor-derived peptide fragments
WO2009004315A8 (en) Isolated peptides and uses thereof
ATE466030T1 (en) NEW SCREENING PROCESS
DE602005021858D1 (en) PEPTIDES OF THE AMYLIN FAMILY, PROCESS FOR THEIR PREPARATION AND USE
GB2431404A (en) Peptide
EP2264065A3 (en) Novel Insulin Derivatives
UA103154C2 (en) Hla-a*-1101-restricted wt1 peptide and pharmaceutical composition comprising thereof
IL173532A0 (en) Compounds comprising lpa
DE602007014210D1 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
WO2005089118A3 (en) Novel bicyclic compounds as modulators of androgen receptor function and method
EP2264066A3 (en) Novel insulin derivatives
BRPI0412607A (en) method for enhancing the efficacy of biological reaction modifying proteins and resulting muteins
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2007045247A3 (en) Fibroblast growth factor receptor-derived peptides
WO2001047956A3 (en) Method for obtaining proteins having improved functional characteristics
WO2006091727A3 (en) Single branch heparin-binding growth factor analogs
Mann et al. The amino acid sequence of a type I copper protein with an unusual serine‐and hydroxyproline‐rich C‐terminal domain isolated from cucumber peelings
IL183779A0 (en) Vitamin d receptor modulators
EA010786B1 (en) Peptide cyclisation
WO2005025514A3 (en) Compounds that modulate neuronal growth and their uses
WO2007045243A3 (en) Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
WO2007131973A3 (en) Compositions and methods for modulating the immune system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008535889

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006791473

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006791473

Country of ref document: EP